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ABSTRACT 1 
Lactic acid bacteria (LAB) isolated from soymilk were used to produce a 2 
multifunctional fermented food. Seven isolates were screened for their ability to 3 
produce peptides and free isoflavones in soymilk. The antihypertensive, antioxidant and 4 
antiinflammatory properties of the resulting fermented soymilks were evaluated in vitro 5 
using biochemical assays. Isolates 1-5 were found to be producers of fermented soymilk 6 
with angiotensin-I converting enzyme inhibitory activity (ACEI). Isolate 3 was found to 7 
be producer of free isoflavones which increased the antioxidant and anti-inflammatory 8 
potential of fermented soymilk. LAB isolates 2-5 were submitted to genetic profiling 9 
and characterization scheme. These isolates were identified as E. faecium and none of 10 
them contained virulence determinants or resistance to antibiotics. In conclusion, our 11 
study shows that the application of E. faecium isolate 3 for multifunctional food 12 
production from soymilk could be a promising strategy in the prevention therapy 13 
against CVD. 14 
Keywords: soymilk, Enterococcus faecium, isoflavones, peptides, hypertension, 15 
oxidative stress, inflammation. 16 
3 
 
INTRODUCTION 17 
Cardiovascular diseases (CVD) remain the highest cause of deaths worldwide. 18 
According to the World Health Organization
1
, more than 17 million people died from 19 
CVD in 2008. Although the current economic burden of CVD is enormous, the cost is 20 
projected to get higher in the future. Hypertension and atherosclerosis are two closely 21 
related pathological conditions, both of which are major risk factors of CVD
2
. Blood 22 
pressure is regulated partially by rennin-angiotensin-aldosterone system. Angiotensin I 23 
converting enzyme (ACE) (E.C. 3.4.14.1) is the main component of this system
3
. ACE 24 
modulates arterial blood pressure converting angiotensin I, an inactive decapeptide, into 25 
angiotensin II, an octapeptide with potent vasoconstrictor action
3
. Moreover, ACE 26 
degrades bradykinin which exerts an important vasodilation activity. Inhibition of ACE 27 
by natural or synthetic inhibitors has been shown to reduce blood pressure in 28 
experimental animals and humans
4
.  29 
Scientific evidence links oxidative stress to the development of hypertension
5
 30 
and atherosclerosis
6
. Enhanced production of reactive oxygen species (ROS) may give 31 
rise to hypertension by decreasing nitric oxide availability for smooth muscle 32 
relaxation. In addition, oxidative stress promotes inflammatory processes that result in 33 
the formation of atherosclerotic lesions
7
. Therefore, increasing cellular antioxidant 34 
capacity, reducing oxidative stress and associated inflammation can provide the 35 
beneficial effect to improve vascular health and prevent and/or inhibit the development 36 
of CVD
8
.  37 
Nutritional interventions including either dietary changes (increasing intake of 38 
fruits, vegetables and whole grains, reducing foods containing sugars and high sodium 39 
levels, etc) or consumption of functional foods containing cardioprotective compounds 40 
(polyphenols, vitamins, fatty acids, carotenoids, soluble dietary fibers, sterols, 41 
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organosulfur compounds, monoterpenes, etc) have been suggested as an approach to 42 
fight against CVD
9
. A promising strategy in the prevention of CVD could be the 43 
development of multifunctional foods containing antioxidant, anti-inflammatory and 44 
angiotensin-converting enzyme inhibitory (ACEI) compounds to target the multiple 45 
pathological conditions of CVD. In particular, soymilk contains bioactive compounds 46 
which may have beneficial roles in cardiovascular health promotion. Soymilk protein 47 
supplemented to a high-fat diet lowered concentration of plasma lipids, total cholesterol, 48 
triglycerides and free fatty acids in C57BL/6N mice
10
. Fermented soymilk with lactic 49 
acid bacteria (LAB) has been proven as a source of ACEI peptides. ACEI peptides are 50 
released from precursor inactive soybean proteins by the action of microbial proteases 51 
during fermentation of soymilk
11
. On the other hand, fermentation with -glucosidase-52 
producing LAB has shown a great potential for the enrichment of bioactive aglycone 53 
isoflavones in soymilk
12
. The most abundant isoflavones in soybean are malonyl-, 54 
acetyl- and -glucoside conjugates of genistein and daidzein13 which are poorly 55 
absorbed in the small intestine and less bioactive as compared with their aglycone 56 
isomers
14
. -Glucosidases hydrolyze the -glycosyl bond of the -glucoside isoflavone 57 
to form the aglycone isomer. Aglycone isoflavones have been reported as dietary 58 
modulators of cardiovascular function by regulation of vascular tone, oxidative stress, 59 
antioxidant gene transcription
9,15
 as well as modulators of inflammatory processes
16
.  60 
In this study, we explored for the first time the potential application of LAB 61 
isolated from soymilk as functional cultures able to form bioactive compounds with 62 
ACEI, antioxidant and anti-inflammatory properties.  63 
 64 
 65 
 66 
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MATERIALS AND METHODS  67 
Chemicals. Unless otherwise stated, all chemicals and reagents were obtained from 68 
Sigma-Aldrich (Barcelona, Spain). MRS agar, M17 broth and growth media 69 
supplements were obtained from Pronadisa (Madrid, Spain). Baird-Parker agar, 70 
Columbia agar and API 50 CHL galleries were purchased from Biomerieux (Marcy 71 
L´etoile, France). Kanamycin Aesculin Azide Agar (KAA) was obtained from Oxoid 72 
(Basingstoke, UK). Todd-Hewitt broth was provided by Difco (Detroit, MI, USA). 73 
Genistein, daidzein and glycitin standards were purchased from Extrashynthese SAS 74 
(Genay, France). 75 
Materials. Soybeans were provided by MangFong S.A. (Madrid, Spain). Reference 76 
LAB strains Lactobacillus delbrueckii subsp. lactis CECT 372, Streptococcus 77 
thermophilus CECT 986, Lactobacillus plantarum CECT 784 were provided from the 78 
Spanish Type Culture collection (Valencia, Spain). The reference strains were 79 
subcultured in appropriate media and stored at -80 ºC in the presence of glycerol (20%, 80 
v/v). Commercial fermented milk containing ACEI peptides was purchased in a local 81 
supermarket. 82 
Soymilk preparation. Soymilk was prepared according to Champagne et al. (2009) 83 
with some modifications. Briefly, soybeans were soaked in distilled water at 1:4 ratio 84 
(w:v) for 16 h at 20 ºC. Subsequently, 190 g of soaked beans in 500 mL of distilled 85 
water were ground in a Thermomix blender (Vorwerk, Germany) at 50 ºC and 86 
maximum speed for 3 min. The slurry was vacuum-filtered on Whatman n.1 paper and 87 
autoclaved at 115 ºC for 15 min. 88 
Isolation and selection of LAB. Raw soymilk supplemented with 5% glucose (w/v) 89 
and 3% NaCl (w/v) was incubated at 30 ºC for 24, 48 and 72 h. Serial decimal dilutions 90 
(10-10
8
) of fermented soymilk in peptone water at each incubation time were plated in 91 
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duplicate onto MRS agar, a medium for the isolation of LAB and bifidobacteria, and 92 
M17 containing 0.5% (w/v) lactose, a medium for the isolation of lactococci and 93 
Streptotococcus thermophilus. MRS and M17 plates were incubated anaerobically (85% 94 
nitrogen, 10% hydrogen, 5% carbon dioxide) at two different temperatures (30 ºC and 95 
37 ºC) for 48 h.  96 
Ten isolates from each culture on which growth was observed (50 isolates per 97 
sample) were randomly selected, grown in LAPTg broth (1% meat peptone, 1.5% 98 
tryptone, 1% yeast extract, 1% glucose and 0.1% Tween 80) and stored at -80 ºC in the 99 
presence of glycerol (20%, v/v). The isolates were observed by optical microscopy to 100 
determine the morphology and Gram staining and, additionally, catalase and oxidase 101 
tests were performed to select lactic acid bacteria. A total of seven Gram positive, 102 
catalase-negative and oxidase-negative isolates were randomly selected for further 103 
assays as presumptive lactic acid bacteria. After this initial selection, LAB were first 104 
characterized for their growth, acidification rate, proteolytic activity and isoflavone 105 
bioconversion in sterile soymilk incubated at 37 ºC for 16 h. Fermented soymilk by 106 
isolated strains was further screened for ACEI activity, oxygen radical absorbance 107 
capacity (ORAC) and nitric oxide inhibitory (NOI) activity.  108 
Culture preparation and fermentation of soymilk. Stock cultures of  reference strains 109 
and isolated LAB were thawed, inoculated at 2% (v/v) in their corresponding growth 110 
medium (LAPTg for isolated LAB, MRS for Lactobacillus CECT strains and M17 111 
supplemented with 0.5% lactose for S. thermophilus CECT 986) and incubated at 37 ºC 112 
for 20 h. Further, cultures were transferred at 2% (v/v) to sterile soymilk and incubated 113 
at 37 ºC for 8 h (S. thermophilus CETC 986), 10 h (L. lactis CETC 372) and 16 h (L. 114 
plantarum CECT 784 and isolated LAB). Finally, soymilk was inoculated with the 115 
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bacterial cultures at 1 × 10
6
 CFU/mL to initiate the respective fermentations, which 116 
were carried out at 37 ºC for 16 h.  117 
Bacterial growth, acidification and proteolytic activity. At the end of fermentation, 118 
bacterial growth was determined by plating decimal peptone water dilutions (10
6
-10
8
) of 119 
the fermented samples in triplicate onto appropriate medium for each culture. The pH 120 
value of the fermented soymilk was measured with a pHmeter (Crison Instruments S.A., 121 
Barcelona, Spain).  122 
Proteolytic activity of LAB was assessed by measuring the free amino groups in 123 
the whey fraction of fermented soymilk following the method reported by Adler-124 
Nissen
17
. The absorbance of the samples was measured at 340 nm in a microplate reader 125 
(Biotek, USA). An external calibration curve was prepared with L-Leucine from 0.2 to 126 
4 mM. Unfermented soymilk was used as blank and was subtracted from each sample 127 
value to calculate the concentration of peptides produced by fermentation and results 128 
were expressed as mg peptides/mL of sample. 129 
Isoflavone extraction and analysis. Isoflavones from freeze-dried samples were 130 
analysed by RP-HPLC and HPLC-MS according to Dueñas et al.
18
. Chromatographic 131 
peaks were identified by comparison of retention times, UV and mass spectra with those 132 
of standards. Maximum UV wavelength and m/z ratios of molecular and fragment ions 133 
were used for identification of each compound as shown in Table 1. Quantification was 134 
made using external calibration curves (linearity of calibration was >0.999; standard 135 
concentration range 0-25 µg/mL), with genistein, daidzein and glycitin standards. The 136 
concentrations of malonyl, acetyl, glucoside and aglycone forms were calculated using 137 
the calibration conversion factors shown in Table 2 and reported by Collison
19
. 138 
ACEI activity. ACEI activity was determined in whey fractions of fermented soymilk. 139 
Whey fraction was obtained by sample stirring and centrifugation at 20,000 × g at 4 ºC 140 
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for 10 min. ACEI activity was measured following the fluorescence-based protocol of 141 
Santandreu and Toldrá
20
. The generated fluorescence was read every minute for 30 min 142 
at emission and excitation wavelengths of 355 and 405 nm, respectively, in a microplate 143 
fluorometer (Biotek, USA). ACEI activity was expressed as the protein concentration 144 
(g/mL) needed to inhibit 50% of ACE activity (IC50). IC50 values were determined by 145 
dose–response curves in which the range of concentrations (0-160 g protein /mL) was 146 
distributed in a logarithmic scale and using the non-linear regression sigmoidal curve fit 147 
function in GraphPad Prism 4.00 (Graphpad Software Inc., San Diego, CA, USA). 148 
Protein concentration was measured by Biorad DC
TM
 protein assay (Biorad, Spain) 149 
using bovine serum albumin as standard. 150 
Oxygen radical absorbance capacity (ORAC). Oxygen Radical Absorbance Capacity 151 
(ORAC) was measured by fluorescence as described previously
21
. Results were 152 
expressed as mg Trolox equivalents (TE) per gram of dry matter (mg TE/g d.m.).  153 
Nitric oxide inhibitory (NOI) activity. Murine macrophages RAW 264.7 from 154 
American Type Culture Collection (ATCC, Manassas, VA, USA) were used to measure 155 
the potential anti-inflammatory activity of fermented soymilk. Macrophages were 156 
cultured in DMEM containing 1% penicillin/streptomycin, 1% sodium pyruvate, and 157 
10% fetal bovine serum at 37 ºC in 5% CO2/95% air as described elsewhere
21
. The cells 158 
(5 × 10
4
/well) were treated with 1 µg/mL of lipopolysaccharide (LPS) from Escherichia 159 
coli O55:B5 and the 10-fold diluted whey fraction of fermented samples (50 g of 160 
protein/mL), for 24 h. Medium was collected after treatment and nitrite accumulation, 161 
an indicator of NO synthesis, was measured in the culture medium by Griess reaction. 162 
Cell viability was conducted using the CellTiter 96 Aqueous One Solution Proliferation 163 
assay kit from Promega (Barcelona, Spain) following manufacturer´s instructions. 164 
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Identification of the bacterial isolates. LAB isolates 2, 3, 4 and 5 were tested for 165 
coagulase activity and for growth on plates of Baird-Parker, a selective medium for the 166 
isolation of staphylococci, and Kanamycin Aesculin Azide Agar, a selective medium for 167 
the isolation of enterococci. The fermentation of carbohydrates was also assessed using 168 
API 50 CHL galleries. Phenotyping of selected strains indicated that they belonged to 169 
the genus Enterococcus, therefore, identification was performed by PCR species-170 
specific detection of enterococcal ddl genes, which encode D-alanine:D-alanine ligases, 171 
following the protocol described by Dutka-Malen et al.
22
.  172 
Confirmation of enterococci identification was performed by PCR sequencing of 173 
a 470 pb fragment of the 16S rRNA gene as described by Kullen et al.
23
. The amplicons 174 
were purified using the Nucleospin Extract II kit (Macherey-Nagel, Düren, Germany) 175 
and sequenced at the Genomics Unit of the Universidad Complutense de Madrid, Spain. 176 
The resulting sequences were used to search sequences deposited in the EMBL database 177 
using BLAST algorithm and the identity of the isolates was determined on the basis of 178 
the highest scores (>98%). 179 
Phenotypic assays of enterococcal isolates. The hemolytic activity of the isolates was 180 
determined on Columbia agar supplemented with 5% horse blood. After an incubation 181 
of 72 h at 37 C, the plates were analyzed and the isolates were classified as non-182 
hemolytic (no halo), moderately hemolytic (halo<1.5 mm) or strongly hemolytic 183 
(halo>1.5 mm). 184 
Production of gelatinase was determined on Todd-Hewitt agar containing 30 g of 185 
gelatin per liter. Single colonies were streaked onto plates, grown overnight at 37 °C, 186 
and placed at 4 °C for 5 h before examination for zones of turbidity around the colonies, 187 
indicating hydrolysis. 188 
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Screening for potential virulence determinants, van genes and antibiotic 189 
susceptibility among the enterococcal isolates. Screening for potential virulence 190 
determinants, van genes and antibiotic susceptibility among the enterococcal isolates 191 
was performed. A multiplex PCR method was used to detect the presence of virulence 192 
determinants encoding sex pheromones (ccf, cpd, cad, cob), adhesins (efaAfs, efaAfm) 193 
and products involved in aggregation (agg2), biosynthesis of an extracellular 194 
metalloendopeptidase (gelE), biosynthesis of cytolysin (cylA) and immune evasion 195 
(epsfs)
24
. The primers couples and PCR conditions used to detect all the genes cited 196 
above were those proposed by Eaton and Gasson
25
. Control strains used in PCR 197 
experiments were E. faecalis strains F4 (efaAfs
+
 gelE
+
 agg
+
 cylMBA
+
 esp
+
 cpd
+
 cob
+
 198 
ccf
+
 cad
+
), P36 (efaAfs
+
 gelE
+
 agg
+
 cylA
+
 esp
+
 cpd
+
 cob
+
 ccf
+
 cad
+
) and P4 (efaAfs
+
 199 
gelE
+
 agg
+
 cylA
+
 cpd
+
 cob
+
 ccf
+
 cad
+
), and E. faecium P61 (efaAfm
+
 esp
+
)
25
.  200 
PCR reactions for vanA and vanB genes were prepared as described by Dutka-201 
Malen et al.
22
 and Ramos-Trujillo et al.
26
, respectively. E. faecium BM4147 (resistant to 202 
vancomycin, VanA
+
) and E. faecalis V583 (resistant to vancomycin, VanB
+
) were used 203 
as positive controls. Detection of vanD, vanE and vanG genes in the E. faecalis isolates 204 
was performed as previously described
27-29
.  205 
The determination of the MIC (minimal inhibitory concentration) to several 206 
antibiotics was evaluated by a microdilution method using the Sensititre plates Staenc1F 207 
(Trek Diagnostic Systems, Cleveland, OH, USA) as described by Jiménez et al.
24
.  208 
Data analysis. Experiments were performed in duplicate; each replicate was analysed at 209 
least in duplicate. Data were expressed as means ± standard deviation of two 210 
independent experiments. The statistical methods used were: one-way analysis of 211 
variance (ANOVA) to determine whether there were significant (P0.05) differences 212 
between samples using Statgraphics 5.0 (Statistical Graphics Corp, Rockville, MD, 213 
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USA) software. Pattern recognition methods such as principal component analysis 214 
(PCA) and hierarchical cluster analysis (HCA) were applied to the data collected from 215 
each sample using The Unscrambler X (CAMO, Norway) software package. PCA was 216 
applied to the data set after standardisation (the mean of the values for each variable is 217 
subtracted from each variable value and the result is divided by the standard deviation 218 
of the values for each variable). HCA was applied to the standardised data to investigate 219 
similarities and sample types.  220 
 221 
RESULTS  222 
Growth, acidification and proteolytic activity of bacterial isolates in soymilk. Table 223 
3 shows the bacterial growth, pH, and the proteolytic activity of LAB isolates and 224 
reference strains. Bacterial isolates grew well in soymilk, attaining values of ΔLog 225 
CFU/mL which ranged from 1.5 to 2.46. The cell density values for all isolates (8.09-226 
8.96 Log CFU/mL) were similar or even higher (P<0.05) compared to the reference 227 
strains Lb. plantarum CECT 784 (LP), Lb. delbrueckii subsp. lactis CECT 372 (LL) and 228 
S. thermophilus CECT 986 (ST).  229 
With regard to acidification activity, all isolates underwent a process of lactic 230 
acidification (Table 3). After 16 h of incubation at 37 ºC, the ΔpH values ranged from 231 
1.68 to 2.23 units. The pH values of soymilk fermented with the bacterial isolates (pH 232 
range from 4.27 to 4.82) were slightly higher (P<0.05) compared to LP and LL. In 233 
addition, soymilk fermentation with isolates 2, 3, 5 and 7 showed similar pH values to 234 
those observed in fermented soymilk with ST; however, isolates 1, 4 and 6 showed the 235 
lowest (P<0.05) acidification activity.  236 
Proteolytic activity was expressed as the peptide content released during 237 
fermentation (Table 3). Isolate 7 showed the lowest proteolytic activity (P<0.05). In 238 
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contrast, isolate 2 exhibited the highest proteolytic activity which was similar to LL. 239 
The other isolates 1, 3, 4, 5 and 6 exhibited an intermediate proteolytic activity which 240 
was similar to ST and LP. 241 
 242 
Biotransformation of isoflavones in fermented soymilk with bacterial isolates. The 243 
concentration of isoflavone glucosides in non-fermented soymilk (NFS) was 85.48 g/g 244 
fresh weight (f.w.) (Table 4). In addition, daidzin and genistin accounted for 32% and 245 
46% to the total isoflavone glucoside concentration, respectively. Low concentrations of 246 
isoflavone aglycones were also observed (18.80 g/g f.w.) being genistein the most 247 
abundant aglycone found in NFS (11.12 g/g f.w.). Biotransformation of isoflavones in 248 
soymilk during fermentation was strain specific. Isoflavone glucosides (glycitin, 249 
genistin and daidzin) markedly decreased (P<0.05) in soymilk fermented with isolate 3 250 
and LP and, in a lesser extent in LL. In general, malonylglucoside content of soymilk 251 
was stable after fermentation, with the exception of isolate 3, 5 and LL. In contrast, 252 
lactic acid fermentation decreased (P<0.05) acetylglucoside isoflavone concentration of 253 
soymilk. With regard to aglycones, fermentation with isolate 3 and LP increased 3- and 254 
4-fold the aglycone content, respectively. As an example, Figure 1 compares the 255 
isoflavones chromatographic profile of NFS and soymilk fermented with isolate 3. In 256 
soymilk fermented by isolate 3 and LP, the concentration of aglycones reached 71% and 257 
82% of the total isoflavone concentration. The highest concentration of daidzein and 258 
genistein was found in soymilk fermented with isolate 3 (34.32 g/g f.w. and 28.07 259 
g/g f.w., respectively) and LP (43.06 g/g f.w., 31.99 g/g f.w., respectively). 260 
Compared to other aglycones, the concentration of glycitein was much lower in all 261 
fermented soymilks. Higher glycitein concentrations were only found in soymilk 262 
fermented with LL (2.58 g/g f.w.), isolate 3 (2.92 g/g f.w.) and LP (5.6 g/g f.w.). 263 
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ACEI, antioxidant and NOI activities of fermented soymilk with bacterial isolates. 264 
Table 5 shows the ACEI activity, expressed as IC50, of NFS soybean milk (101.6 g 265 
soluble protein/mL) and fermented soymilks (24.26 to 79.78 g soluble protein/mL) 266 
compared to NFS. These results indicate that ACEI activity is enhanced (P<0.05) by 267 
fermentation with all LAB tested. However, differences among isolates were observed, 268 
as it is shown in the dose-response curves of some LAB isolates illustrated in Figure 2. 269 
With the exception of isolate 6 and 7, ACEI activity of fermented soymilk was higher 270 
(P<0.05) compared to ST and LP, and similar to LL. Soymilk fermented with isolate 2 271 
showed the highest (P<0.05) ACEI activity (IC50 = 24.26 g protein/mL) followed by 272 
isolates 1, 3, 4 and 5 (IC50 = 34.26-39.5 g protein/mL). The ACEI activity of 273 
fermented soymilks containing isolates 1-5 was up to 2-fold higher (P<0.05) compared 274 
to a commercial fermented bovine milk containing ACE-inhibitory peptides (IC50 = 275 
49.62 g protein/mL) (data not shown).  276 
Soymilk fermentation with LAB isolates 1, 4, 5, 6 and 7 showed similar ORAC 277 
values (1.15-1.38 mg Trolox/g f.w.) to NFS (1.31 mg Trolox/g f.w.). In contrast, 278 
soymilk fermented with isolate 2, 3 and LP showed higher (P<0.05) ORAC values 279 
(1.52, 1.75, 2.02 mg Trolox/g f.w.) compared to NFS. 280 
Soymilk samples did not show significant effect on the macrophage RAW264.7 281 
cell proliferation (data not shown) at the concentrations tested (10-fold dilutions of the 282 
whey fraction corresponding to 40 ± 0.39 g of soluble protein/mL of medium). 283 
Subsequently, macrophages activated with LPS (1 g/mL) were treated for 24 h with 284 
NFS and fermented samples (10-fold dilutions of the whey fraction corresponding to 40 285 
± 0.39 g of soluble protein/mL of medium). Cells treated with LPS and sample vehicle 286 
(water) showed increased release of NO in the medium (data not shown) which mimics 287 
the inflammatory status of macrophages. NFS and fermented soymilk with isolates 1, 2, 288 
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4-7, ST and LL showed a weak inhibition of the NO production in LPS-activated 289 
macrophages ranging from 23% to 30% (Table 4). On the contrary, fermented soymilk 290 
with isolate 3 and LP markedly inhibited (P<0.05) the NO production (46.64% and 291 
48.78%, respectively) in LPS-stimulated macrophages. 292 
Principal component and hierarchical cluster analysis. The score and loading plots 293 
for PC1 vs. PC2 are superimposed in Fig. 3. PC1 explained 68% of the total variance in 294 
the data set while PC2 explained 30%. The location of soymilk fermented by isolate 3 295 
and LP may be explained by their higher values in aglycones, ORAC and NOI activity. 296 
In contrast, soymilk fermented by isolates 1, 4, 5, 6, 7 and LL showed lower aglycones, 297 
ORAC and NOI activity, therefore, they are located diametrically opposite to LP and 298 
isolate 3. The location of fermented soymilk with isolate 2 may be explained by its high 299 
peptide content and ACEI activity which is opposite to the location of fermented 300 
soymilk with ST characterized by its lower peptide content and ACEI activity. 301 
Aglycone content was found to be significantly correlated (P<0.05) with ORAC and 302 
NOI activity as evidenced their Pearson correlation coefficients (r=0.898 and 0.952, 303 
respectively). In addition, ORAC and NOI activity were also positively correlated 304 
(r=0.871; P<0.05).  305 
The results obtained following HCA are shown as a dendogram in which four 306 
well-defined clusters are found (Figure 4). Samples are grouped in clusters based on 307 
their relative distance. Group I included soymilk fermented with isolate 2 which showed 308 
the highest ACEI activity. Group II comprised soymilk fermented with ST with low 309 
aglycone content, ACEI, ORAC and NOI activity. Fermented samples obtained with LP 310 
and isolate 3 were clustered in group III because of the highest levels of aglycones, 311 
ORAC and NOI activity. Finally, soymilks fermented with isolates 1, 5, 6, 4, 7 and LL 312 
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were clustered (Group IV) based on their moderate ACEI activity and low aglycone 313 
content, ORAC and NOI activity.  314 
Identification and characterization of bacterial isolates. Isolates 1, 2, 3 and 5 were 315 
selected for identification based on PCA and HCA. The selected isolates were identified 316 
by classical morphological and biochemical tests, species-specific PCR and/or 16S 317 
rDNA sequencing. All the selected isolates were identified as Enterococcus faecium. 318 
None of the E. faecium strains was haemolytic or showed gelatinase activity and none 319 
of them contained any virulence determinant (ccf, cpd, cad, cob, efaAfs, efaAfm, agg2, 320 
gelE, cylA, epsfs). All the E. faecium strains were susceptible to low concentrations (≤4 321 
µg/mL) of penicillin, ampicillin, ciprofloxacin, fosfomycin, nitrofurantoine, 322 
tetracycline, erythromycin, vancomycin, teicoplanin, chloramphenicol and rifampicin. 323 
 324 
DISCUSSION 325 
The use of enterococci in the food industry is still controversial. Enterococci have been 326 
found as opportunistic pathogens that cause nosocomial infections in patients with 327 
underlying diseases and in neonates. Factors contributing to pathogenesis are their 328 
resistance to a variety of antibiotics and virulence factors such as aggregation 329 
susbstance, gelatinase, extracellular superoxide, and extracellular surface protein
30
. 330 
Therefore, in order to select an enterococcal strain as a potential starter candidate, the 331 
susceptibility to clinically relevant antibiotics and the presence of virulence 332 
determinants, were thoroughly investigated in the present study. The E. faecium strains 333 
selected in this study showed absence of virulence determinants and/or any other factor 334 
of clinical significance, such as the antibiotic resistance pattern or gene transfer 335 
potential which indicates that the isolated E. faecium strains is safe. 336 
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Results from PCA and HCA showed that fermented soymilks with isolates 2 and 337 
3 were quite different from soymilks fermented with isolates 1 and 4-7 which indicates 338 
that different strains of E. faecium were isolated from soymilk. E. faecium strains have 339 
also been isolated from other traditional fermented foods
 
in which E. faecium strains 340 
play an important role in the organoleptic characteristics of these products
31,32
. 341 
Moreover, certain strains of E. faecium have contributed to the health benefits of 342 
fermented foods. Fermented products containing E. faecium CRL 183 as adjunct starter 343 
culture was found to be effective in reducing serum total cholesterol and atherosclerotic 344 
lesions in animal models
33, 34
. E. faecium SF68 has been proposed to be clinically 345 
effective against antibiotic-associated diarrhea
35
. E. faecium also produced heat stable 346 
enterocins capable of inhibiting food-spoiling or pathogenic bacteria such as 347 
Helicobacter pylori, Listeria sp., or Staphylococcus aureus
36
. 
 
348 
All studied isolates grew well in soymilk, attaining almost the same cell counts 349 
(8.5 log CFU/mL) found for other LAB
37
. From screening, all studied isolates 350 
demonstrated proteolytic activity in soymilk at 37 ºC, although enterococcus species are 351 
not generally considered highly proteolytic
38
. Differences of peptides accumulated in 352 
soymilk during fermentation among LAB isolates might be strain-specific as it has also 353 
been observed by other researchers
37
. Recently, intra and extracellular proline, arginine, 354 
lysine, leucine, valine and cysteine aminopeptidase activities have been observed in 355 
different species of enterococci which were found strain-dependent
31
. These 356 
aminopeptidase activities are associated with flavor development in fermented 357 
products
38
, however, they could play an important role in the release of bioactive 358 
peptides. Our results have shown that soymilk fermented with pure cultures of E. 359 
faecium exhibit ACEI activity significantly higher to other LAB such as S. thermophilus 360 
and L. plantarum. Moreover, IC50 values of soymilk fermented by E. faecium showed in 361 
17 
 
this study were markedly lower to those reported by other authors in fermented milk 362 
with Lb. helveticus
39
 which is commercially used for the production of fermented dairy 363 
products claiming hypotensive effects. Recently, E. faecalis and E. faecium have been 364 
used as starters for the production of fermented milk and cheese with ACEI activity
32,39
. 365 
Our results show for first time the application of E. faecium as starter culture to produce 366 
a fermented soymilk with ACEI activity.  367 
Isoflavone contents found in the present work in NFS (heated at 115 ºC for 15 368 
min) were different from those found in the literature for soymilk processed by different 369 
thermal methods
40
. Soymilk heated at 115 ºC for 15 min showed lower total glucosides 370 
but higher total aglycones than soymilks processed by direct steam injection (100 ºC 20 371 
min) as well as direct and undirect Ultra-High temperatures (143 ºC, 60 s). Thermal 372 
processing may cause the intertransformation and degradation of isoflavones which 373 
explains different isoflavone contents in soymilks processed by different thermal 374 
methods. Besides thermal processing, fermentation with LAB may have a significant 375 
impact on the transformation of isoflavones. Among the bacterial isolates tested, only E. 376 
faecium 3 showed a significant bioconversion of the glucoside isoflavones into their 377 
corresponding aglycones after 16 h of soymilk fermentation. Total aglycones reached 378 
71% of the total isoflavone content in soymilk fermented by E. faecium isolate 3 which 379 
was close to that found in fermented soymilk with L. plantarum, considered a high -380 
glucosidase-producing LAB
41
. -glucosidase activity has been found to be strain and 381 
time dependent
12
. For instance, -glucosidase activity of E. faecium 35 and L. 382 
paraplantarum KM rapidly increase up to 6 h of fermentation
42
. In contrast, Pyo et al.
43
 383 
observed that -glucosidase activity of L. plantarum and L. delbrueckii increased up to 384 
24 h of fermentation. A recent approach to enhance isoflavone bioconversion during 385 
soymilk fermentation was the ultrasound treatment of probiotic cultures at 100 W for 3 386 
18 
 
min
44
. The ultrasound treatment facilitates β-glucosidase excretion from the cells and 387 
the transfer of substrates (glucosides) and products (aglycones) through cells 388 
membranes. It is well established that the synthesis of isoflavone aglycones improves 389 
the bioavailability and biological functionality of soymilk via passive diffusion across 390 
the intestinal brush border
45
.  391 
Oxidative stress has been implicated as a causal factor in diseases such as 392 
hypertension and atherosclerosis. Superoxide radicals react with nitric oxide, forming 393 
peroxynitrite that promotes inflammatory responses by activation of the transcriptional 394 
factor NF-kB which results in the formation of atherosclerotic lesions
7
. Therefore, 395 
decreasing oxidative stress and inflammation have been suggested as strategy for 396 
prevention and/or amelioration of CVD. Hence, in our study antioxidant and NOI 397 
activities were screened in order to select starter cultures suitable for the production of 398 
multifunctional fermented soymilk to target CVD. The current study shows that soymilk 399 
fermented by E. faecium isolate 3 and L. plantarum exhibit a significant oxygen radical 400 
absorbance capacity. ORAC was positively correlated with isoflavone concentration in 401 
fermented soymilk which indicates that scavenging activity of fermented soymilk might 402 
be attributed to aglycones. The free radical scavenging activities of the flavonoids is 403 
well documented
46
. It has been also described that the degree of hydroxylation is 404 
positively correlated with the antioxidant potential
47
 which explains that aglycone 405 
isomers of isoflavones exhibit higher radical scavenging activity than glucoside 406 
isomers. Therefore, higher ORAC values observed in soymilk fermented with E. 407 
faecium isolate 3 and L. plantarum could be attributed to an effective bioconversion of 408 
isoflavones which agrees with previous studies
43
.  409 
Biomarkers of inflammation have been applied to predict the risk of 410 
atherosclerosis. This study have used macrophages RAW267.4 induced by treatment 411 
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with LPS (1 g/mL) and the nitric oxide concentration released to the medium was 412 
measured as biomarker of inflammation. LPS activates the transcription factor NF-kB 413 
which translocates to the nucleus regulating gene expression involved in the synthesis 414 
of pro-inflammatory mediators such as prostaglandins (PG), cytokines and nitric oxide 415 
(NO). Under physiological conditions, NO is synthesized by constitutive nitric oxide 416 
synthase (cNOS) at nanomolar concentrations, acting as cellular messenger and 417 
regulating a broad range of biological functions such as smooth muscle relaxation, 418 
cardiac and skeletal muscle contractility, platelet adhesion and aggregation, metabolism 419 
of lipids, glucose and amino acids, neuronal activity and immune response
48
. In the 420 
immune system, NO may exert both anti- and pro-inflammatory effects. During 421 
inflammation, a greatly increased NO level produced from induced NOS (iNOS) in 422 
immune cells lead to formation of peroxynitrite in high amount which may further 423 
increase inflammatory response. Fermented soymilk with E. faecium isolate 3 and L. 424 
plantarum markedly inhibited nitric oxide production (47% and 49%, respectively) in 425 
LPS-activated macrophages. Therefore, soymilk fermented by E. faecium isolate 3 may 426 
be potentially helpful for the prevention or alleviation of inflammatory processes 427 
associated to CVD. This biological effect was positively correlated (r=0.898) with 428 
aglycone concentration which suggests that aglycones are the bioactive compounds 429 
responsible for the NOI activity observed in fermented soymilk. In consistency with our 430 
results, previous studies have reported the role of genistein, daidzein and daidzein 431 
metabolites such as equol in mediating inflammation. Kao et al.
49
 demonstrated that 432 
isoflavone powder produced from soybean cake inhibited LPS-induced inflammation in 433 
BALB/c mice by lowering the secretions of interleukin-1β, interleukin-6, NO, and 434 
PGE2. Similarly, Dia et al.
50
 found that genistein and daidzein inhibited COX-2/PGE2 435 
and iNOS/NO pathways in LPS-stimulated macrophages. More recently, Di Cagno et 436 
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al.
51
 observed that organic fermented soymilk inhibited the inflammatory status of 437 
Caco-2 cells which were explained by the concomitant activities of aglycones and equol 438 
contained in the soymilk preparation.  439 
In addition to antioxidant and anti-inflammatory activities of isoflavone 440 
aglycones, other beneficial effects have been reported with regard to cardiovascular 441 
health. There are reports showing the blood-pressure and lipid-lowering effects of 442 
aglycones in animal models
33,34,52
. Cardioprotective effects of isoflavones aglycones 443 
have been even observed at nanomolar concentrations (10 nM-300 nM)
15
. The 444 
isoflavones aglycones concentration in soymilk fermented with isolate 3 was 65.6 µg/g 445 
f.w. On the basis of this, the total intake of isoflavone aglycones from two portions of 446 
125 g f.w. of this fermented soymilk per day would provide 16.4 mg/day (7 mg 447 
genistein + 8.6 mg daidzein). The intake of 50 mg aglycone equivalents reveal a plasma 448 
maximum concentration of 2 µM in healthy volunteers
53
. Based on these results, it can 449 
be assumed that consumption of 250 g of fermented soymilk by E. faecium isolate 3 450 
may provide benefits to human health. 451 
In summary, E. faecium isolate 3 is a safe culture which efficiently produces 452 
peptides and isoflavone aglycones providing to soymilk with a combination of 453 
inhibitors of angiotensin I-converting enzyme, antioxidant and antiinflammatory  454 
potential. The application of E. faecium isolate 3 for multifunctional food production 455 
from soymilk could be a promising strategy in the prevention therapy against CVD. 456 
 457 
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FIGURE CAPTIONS 646 
 647 
Figure 1. HPLC chromatograms comparing the isoflavones cromatographic profile of 648 
non-fermented soymilk (     ) and fermented soymilk with isolate 3 (     ). Peak 1: 649 
Daidzin; Peak 2: Glycitin; Peak 3: Genistin; Peak 4: daidzein malonylglucoside; Peak 5: 650 
daidzein acetylglucoside; Peak 6: genistein malonylglucoside; Peak 7: daidzein; Peak 8: 651 
glycitein; Peak 9: genistein acetylglucoside; Peak 10: genistein. 652 
 653 
Figure 2. Dose-response curves for non-fermented (NFS) and fermented soymilk 654 
samples produced by some LAB isolated from soymilk. Values are the average of two 655 
independent experiments. Bars indicate the standard deviation. 656 
 657 
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Figure 3. Principal component analysis (PCA) score and loading biplot. Samples (score 658 
plot) correspond to the soymilks fermented with different LAB strains. Variables 659 
measured (loading plot) correspond to peptides, isoflavone aglycones, oxygen-radical 660 
absorbance capacity (ORAC), inhibition of angiotensin-I converting enzyme(ACEI) and 661 
nitric oxide (NOI).  662 
 663 
Figure 4. Dendogram of hierarchical cluster analysis of the fermented soymilk with 664 
LAB isolates and reference strains. 665 
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Table 1.-Identification of major isoflavones in non-fermented and fermented soymilk samples by 
HPLC-MS. 
 
 
 
 
Peak No. 
UV Wavelength 
(nm) 
[H]
- 
(m/z) 
Fragment 
ions (m/z) 
Isoflavones 
1 249, 313  415 253 daidzein 7-O-glucoside (daidzin) 
2 256, 320 445 283 glycitein 7-O-glucoside (glycitin) 
3 260, 327 431 269 genistein 7-O-glucoside (genistin) 
4 250, 301 501 253, 457 daidzein malonylglucoside 
5 252, 301  457 253 daidzein acetylglucoside 
6 258, 320 518 269, 473 genistein malonylglucoside 
7 250, 298  253  daidzein 
8 258, 327 283  glycitein 
9 260, 315 473 431, 269 genistein acetylglucoside 
10 260 269  genistein 
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Table 2. Calibration conversion factors for soy isoflavones 
 
 
 
 
 Aglycone Glucoside 
Acetyl 
glucoside  
Malonyl 
glucoside 
Daidzein 1.000 0.611 0.555 0.506 
Glycitin 1.570 1.000 1.094 1.193 
Genistein 1.000 0.625 0.570 0.521 
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Table 3. Cell growth, acidification and proteolytic activity (expressed as the content of peptides 
released during soymilk fermentation in mg/mL) of LAB isolates and reference strains 
in soymilk incubated at 37ºC for 16 h. 
 
 
 
 
 
 
 
 
 
 
 
 
Data indicate the mean ± standard deviation of two independent experiments. Means with 
different superscript letters in the same column are significantly different (P<0.05 in one-
way ANOVA) 
NFS = Inoculated non-fermented soymilk; ST = S. thermophilus CETC 986; LL= L. 
delbrueckii subsp. lactis CETC 372; LP = L. plantarum CETC 784. 
 Log10 (CFU/mL) pH 
Peptides 
(mg/mL)  
NFS 6.32 ± 0.24
a 
6.50 ± 0.12
g
  
Isolate 1 8.32 ± 0.1
cd
 4.82 ± 0.08
f 
0.71 ± 0.03
cd 
Isolate 2 8.09 ± 0.3
c
 4.44 ± 0.23
bcd 
0.87 ± 0.04
ef 
Isolate 3 8.27 ± 0.10
cd 
4.54 ± 0.10
cde
 0.61 ± 0.01
bc 
Isolate 4 8.24 ± 0.14
cd
 4.75 ± 0.01
ef
 0.72 ± 0.09
bc 
Isolate 5 8.42 ± 0.12
d
 4.27 ± 0.01
b
 0.63 ± 0.06
bc 
Isolate 6 8.88 ± 0.03
e
 4.78 ± 0.09
ef
 0.63 ± 0.04
bc 
Isolate 7 8.96 ± 0.09
e
 4.33 ± 0.01
bc
 0.49 ± 0.06
a 
ST 7.48 ± 0.03
b
 4.39 ± 0.22
bc 
0.67 ± 0.09
bcd
 
LL 8.43 ± 0.09
d 
3.98 ± 0.01
a 
0.94 ± 0.08
f 
LP 8.37 ± 0.15
d
 3.99 ± 0.01
a 
0.58 ± 0.05
b 
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Table 4. Isoflavone content (g/g f.w.) of fermented soymilks with LAB isolates and reference strains. 
Data indicate the mean ± standard deviation of two independent experiments. Means with different superscript letters in the same row are significantly different (P<0.05 in one-way 
ANOVA) 
NFS = Inoculated non-fermented soymilk; ST = S. thermophilus CETC 986; LL= L. delbrueckii subsp. lactis CETC 372; LP = L. plantarum CETC 784. 
 NFS Isolate 1 Isolate 2 Isolate 3 Isolate 4 Isolate 5 Isolate 6 Isolate 7 ST LL LP 
Glycitin 6.47 ± 0.46d 6.13 ± 0.44cd 5.74 ± 0.26bcd 4.94 ± 0.02b 6.19 ± 0.14d 6.16 ± 0.02cd 6.24 ± 0.25d 6.31 ± 0.11d 6.58 ± 0.22d 5.25 ± 1.04bc 3.72 ± 0.22a 
Genistin 39.51 ± 0.30def 41.93 ± 1.19d 40.65 ± 0.09def 10.93 ± 0.09b 40.30 ± 0.67def 41.26 ± 0.89ef 40.12 ± 1.51de 39.87 ± 1.38def 41.71 ± 1.44f 34.95 ± 2.38c 2.14 ± 0.03a 
Daidzin 26.97 ± 1.65cd 28.42 ± 0.44d 25.81 ± 0.51bcd 2.59 ± 0.16a 25.07 ± 0.71bc 26.64 ± 0.08cd 26.24 ± 1.28cd 26.80 ± 0.55cd 26.71 ± 2.25cd 23.81 ± 1.97b 1.18 ± 0.10a 
Malonylgenistin 5.14 ± 0.44de 4.67 ± 0.04bcd 4.74 ± 0.12bcd 4.22 ± 0.08ab 5.15 ± 0.12de 4.56 ± 0.17abc 4.58 ± 0.11bcd 5.43 ± 0.34e 5.08 ± 0.22cde 4.03 ± 0.10a 5.36 ± 0.49e 
Malonyldaidzin 3.53 ± 0.30bc 3.24 ± 0.08bc 3.23 ± 0.16bc 3.18 ± 0.04abc 3.24 ± 0.06bc 3.15 ± 0.18ab 3.39 ± 0.21bc 3.59 ± 0.24c 3.36 ± 0.11bc 2.78 ± 0.21a 3.57 ± 0.35c 
Acetylgenistin 2.23 ± 0.04d 0.13 ± 0.01a 0.08 ± 0.01a 0.11 ± 0.01a 0.82 ± 0.06b 0.09 ± 0.01a 1.30 ± 0.19cd 1.03 ± 0.06b 0.24 ± 0.02a 1.83 ± 0.00c 1.03 ± 0.03b 
Acetyldaidzin 1.63 ± 0.10e 0.41 ± 0.00a 0.46 ± 0.02a 0.44 ± 0.02a 0.60 ± 0.03ab 0.42 ± 0.03a 1.24 ± 0.09d 0.78 ± 0.04bc 0.44 ± 0.02a 1.39 ± 0.16d 0.96 ± 0.09d 
Total glucosides 85.48 ± 1.61d 81.54 ± 0.93d 80.69 ± 0.97d 26.41 ± 0.09b 81.36 ± 1.71d 82.27 ± 0.45d 83.85 ± 3.92d 83.82 ± 2.52d 84.12 ± 0.91d 74.05 ± 5.87c 17.96 ± 1.31a 
            
Glycitein 1.86 ± 0.16ab 1.83 ± 0.16ab 2.40 ± 0.13cd 2.92 ± 0.25e 1.51 ± 0.13a 1.68 ± 0.10ab 1.78 ± 0.10ab 1.90 ± 0.16ab 2.03 ± 0.06bc 2.58 ± 0.26de 5.60 ± 0.26f 
Genistein 11.12 ± 0.18a 10.23 ± 0.50a 10.90 ± 0.58a 28.07 ± 0.26c 11.68 ± 0.27a 10.93 ± 0.97a 10.04 ± 0.54a 10.56 ± 0.85a 13.94 ± 0.28b   13.54 ± 0.28b 31.99 ± 1.84d 
Daidzein 5.82 ± 0.37a 6.44 ± 0.32ab 6.71 ± 0.30ab 34.32 ± 0.41d 6.51 ± 0.05ab 6.85 ± 0.58ab 6.07 ± 0.21a 7.45 ± 0.13ab 6.87 ± 0.16ab 10.13 ± 0.16c 43.06 ± 2.41e 
Total aglycones 18.80 ± 0.39a 18.54 ± 0.98a 21.11 ± 0.40ab 65.58 ± 0.10d 19.70 ± 0.44ab 18.76 ± 0.29a 17.89 ± 0.43a 19.91 ± 0.56ab 22.47 ± 1.10b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             26.25 ± 0.17c 80.65 ± 4.51e
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Table 5. ACEI activity (expressed as IC50 in mg protein/mL), ORAC (expressed in mg 
Trolox equivalents/ g f.w.) and NOI (expressed as % inhibition of NO production in 
macrophages) activities of fermented soymilk with LAB isolates and reference strains.  
 
Data indicate the mean ± standard deviation of two independent experiments. Means with different 
superscript letters in the same column are significantly different (P<0.05 in one-way ANOVA) 
NFS = Inoculated non-fermented soymilk; ST = S. thermophilus CETC 986; LL= L. delbrueckii subsp. 
lactis CETC 372; LP = L. plantarum CETC 784. 
 
 
 ACEI ORAC NOI  
NFS 101.6 ± 7.09
f 
1.31 ± 0.1
bc 
23.87± 0.92
a
 
Isolate 1 35.11 ± 1.50
b 
1.31 ± 0.07
bc
 24.44± 2.93
a
 
Isolate 2 24.26 ± 0.30
a 
1.52 ± 0.07
e 
25.43± 2.78
abc 
Isolate 3 39.5 ± 3.45
b 
1.75 ± 0.27
f 
46.64± 4.28
d 
Isolate 4 34.26 ± 4.91
b 
1.15 ± 0.06
ab
 24.00± 0.73
a
 
Isolate 5 34.45 ± 2.67
b 
1.38 ± 0.06
cd 
30.38± 3.40
b
 
Isolate 6 79.78 ± 8.87
e 
1.24 ± 0.02
abc 
23.58± 3.41
a
 
Isolate 7 41.98 ± 2.96
bc 
1.28 ± 0.12
bc 
30.51± 2.18
bc 
ST 66.73 ± 0.56
d 
1.46 ± 0.10
de 
26.76± 2.45
abc
 
LL 39.86 ± 3.64
b 
1.09 ± 0.10
a 
26.10± 1.25
abc
 
LP 51.37 ± 0.95
c 
2.02 ± 0.10
g 
48.78± 3.83
d
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Figure 3. 
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